Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

What the paper claimed, and what the underlying evidence showed

This Gut commentary by J.R.F. Walters (March 2000) is a critical appraisal of three simultaneous 1999 papers — Makishima et al. (Science 284:1362–5), Parks et al. (Science 284:1365–8), and Wang et al. (Mol Cell 3:543–53) — establishing bile acids as endogenous FXR ligands Three 1999 FXR ligand discovery papers. The commentary's mechanistic reading is accurate: FXR activation repressed CYP7A (the rate-limiting enzyme of classic bile-acid synthesis) and activated the IBABP promoter via an IR-1 inverted repeat responsive element, with chenodeoxycholic acid the most potent ligand and conjugated bile salts effective only when ASBT was co-expressed Mechanistic details: CDCA potency, IR-1 element, ASBT dependence. Later work confirmed and extended this two-branch logic: hepatic FXR–SHP and intestinal FXR–FGF19/FGFR4 axes both suppress CYP7A1, with notable mouse–human species differences FXR-SHP and FGF19 axes for CYP7A1 regulation.

Did the commentary's predictions hold?

Walters posed four open questions. The colorectal cancer question proved prescient: FXR is now regarded as anti-tumorigenic in colon, with FXR loss increasing adenoma burden in APC-mutant mice and secondary bile acids (DCA, LCA) promoting carcinogenesis via DNA damage and NF-κB FXR loss and secondary bile acids in colorectal cancer Secondary bile acids as colon cancer promoters. The metabolic-therapeutic question also matured: FXR and TGR5 became drug targets for obesity, diabetes, and hyperlipidemia Bile acid signaling as metabolic drug target. The gallstone question remains less resolved; notably, a prospective human study found no significant post-cholecystectomy rise in secondary bile acids (26.7% vs 26.8%, NS; only CDCA shifted, +3.1%, P 0.02–0.05, n=18) No secondary bile acid rise after cholecystectomy (n=18) — relevant context since Walters' commentary targets gallstone biology.

Reported values from the 18-patient study: only CDCA changed significantly, tempering the cholecystectomy–colon cancer hypothesis Walters implicitly raised Quantitative bile acid fractions pre/post surgery.

Blindspots and what would change the verdict

The 1999 primary evidence came from CV1 cell transfection, Caco-2 cells, and rats/mice — no direct human hepatocyte validation at the time; the commentary also underweights non-FXR pathways (PXR, VDR cross-talk) now known to shape bile acid responses Model limitations of the underlying 1999 evidence. Confidence in the core claim (bile acids = physiological FXR ligands) is very high, since three independent groups converged and subsequent knockout and FGF19-axis studies confirmed it; what would revise the field's framing is evidence that non-FXR receptors mediate substantial bile acid feedback in human liver in vivo. One under-appreciated extension Walters did not foresee: FXR also coordinates ileal antimicrobial defense against bacterial overgrowth FXR-dependent gut antimicrobial defense. Author Review: J.R.F. Walters Deeper FXR Critique Run AI Scientist Analysis Make Poster

Feedback:   

Updated: October 26, 2026

 Evolve Explanation

 BGPT Paper Review

Study Novelty

The commentary covers a genuinely landmark 1999 discovery: three independent groups converging on bile acids as FXR ligands, ending FXR's orphan status.

Scientific Quality

As a commentary it is rigorous and balanced, correctly weighting the three primary papers; limitations are inherent to commentary format (no primary data, one unexamined conflict-free framing, rodent/cell-model extrapolation).

Study Generality

The bile acid–FXR axis is a general regulatory principle spanning cholesterol metabolism, enterohepatic circulation, cancer, and metabolic disease.

Study Usefulness

Correctly forecast FXR drug-targeting for cholesterol/cholestasis and flagged the CRC and gallstone questions that drove two decades of follow-up research.

Study Reproducibility

The underlying findings were independently reproduced by three groups simultaneously; the commentary itself synthesizes rather than generates data.

Explanatory Depth

Provides mechanistic depth (IR-1 BARE, ASBT dependence, CDCA specificity, coactivator interaction) connecting ligand to physiological feedback control.